Lisette Hilton
Lisette Hilton is president of Words Come Alive, based in Boca Raton, Florida.
Can we lower drug costs?
Can we lower drug costs?
Experts discuss the forces contributing to costs that are rising faster in the United States than in other countries, as well as what dermatologists can do now to help patients get access to more affordable medications.
Expert derm shares injectable adipolysis pearls
Paving the way in nonsurgical neck rejuvenation, is injectable adipolysis with deoxycholic acid, an option that is compatible with the other injectable cosmetic procedures dermatologists use in facial rejuvenation, according to dermatologist Gary D. Monheit, M.D., who presented at the 2016 ASDS annual meeting.
Three minimally-invasive lipo-based neck treatments
There are three minimally-invasive ways of doing liposuction to improve the neck, and these options cover most cosmetic patients, one expert says.
The 'art' of the cosmetic consult
The 'art' of the cosmetic consult
The art of communication must be mastered to gain patients’ trust and, ultimately, to become better doctors, according to Kathleen M. Welsh, M.D. who presented at the 2016 ASDS annual meeting.
The business of cosmeceuticals: Unplugged
Turning dermatologic knowledge into a successful, profitable part of a practice’s bottom line takes business know-how, according to Rancho Mirage, Calif., dermatologist Wendy E. Roberts, M.D, who presented at the 2016 ASDS annual meeting.
Cosmeceuticals unplugged
There are some tricks of the dermatologists’ trade when it comes to optimizing cosmeceutical use by complementing procedures with products, according to New Orleans, La., dermatologist Mary P. Lupo, M.D.
What’s old is new: Microneedling
Microneedling techniques are mimicking results often associated with laser treatment, according to Tina S. Alster, M.D., director of Washington Institute of Dermatologic Laser Surgery, Washington, DC, who presented “Will Microneedling Replace Lasers?” at the 2016 American Society for Dermatologic Surgery (ASDS) annual meeting in New Orleans.
Novartis announces new Cosentyx data in psoriasis treatment, including long-term study
Researchers presented new data on the use of the fully human IL-17A inhibitor Cosentyx (secukinumab, Novartis) in moderate-to-severe psoriasis, at the 25th European Academy of Dermatology and Venereology (EADV) Congress in Vienna, Austria, September 28 through October 2, 2016.
Large prostate Ca study evaluates RP, radiation, monitoring
Nearly 100% of patients with clinically localized prostate cancer, detected by PSA testing, survive at an average 10 years’ follow-up, regardless of whether they had active monitoring, radical prostatectomy, or radiotherapy, according to new study results.
Moves that could rein in out-of-control drug costs
The third in our series on out-of-control drug costs highlights strategies that should work to stabilize the costs of medications, so that they’re more affordable for patients.

Poll

View Results